Residency · Residency · Emergency Medicine
Status Epilepticus: Aggressive Early Management
Definitions and Epidemiology
Definitions
Status epilepticus is defined as continuous seizure activity lasting more than 5 minutes, or two or more seizures without return to baseline between episodes. Refractory status epilepticus describes seizures that persist despite adequate doses of two appropriate medications (a benzodiazepine plus a second-line agent). Super-refractory status epilepticus refers to seizures that continue or recur more than 24 hours after the onset of anesthetic therapy. The older definition requiring 30 minutes of seizure activity is outdated — treatment should begin at 5 minutes.
Epidemiology
Status epilepticus affects 120,000 to 200,000 patients per year in the United States. Overall mortality is 20 percent, rising to 50 percent in refractory cases. The most common cause in patients with known epilepsy is medication non-adherence or subtherapeutic levels. Other causes include CNS infection, stroke, metabolic derangement, drug toxicity, traumatic brain injury, and tumor.
Types
Generalized convulsive status epilepticus (GCSE) is the most dangerous form, involving tonic-clonic activity with a risk of irreversible neuronal injury after 30 minutes. Non-convulsive status epilepticus (NCSE) involves altered awareness without motor convulsions and requires EEG for diagnosis — importantly, up to 20 percent of patients who stop convulsing are in NCSE. Focal status epilepticus includes epilepsia partialis continua.
Pathophysiology
Phases of SE
Status epilepticus progresses through two phases. During the first phase (0 to 30 minutes), compensatory mechanisms produce hypertension, tachycardia, hyperglycemia, hyperthermia, and lactic acidosis, though neuronal damage has already begun. During the second phase (beyond 30 minutes), decompensation occurs with hypotension, hypoglycemia, worsening hyperthermia, rhabdomyolysis, and failure of cerebral autoregulation. A critical molecular change occurs over time: GABA-A receptor internalization removes benzodiazepine targets from the neuronal cell surface, which is why early, adequate dosing is essential.
Why Under-Dosing is Dangerous
The success rate of first-line benzodiazepines drops from 80 percent when given within 10 minutes to less than 50 percent after 30 minutes. This progressive resistance is driven by GABA receptor internalization. Sub-therapeutic initial doses are the single most common treatment error in status epilepticus management.
Management Algorithm
Phase 1: Stabilization (0-5 Minutes)
Initial management focuses on ABCs: positioning, suctioning, and supplemental oxygen. IV access is established (or IM, IN, or PR routes are prepared). Fingerstick glucose is checked and hypoglycemia is treated immediately (with D50 in adults and D10 in pediatrics). Laboratory studies are drawn, including a BMP, CBC, magnesium, calcium, anticonvulsant levels, toxicology screen, and lactate. Continuous pulse oximetry and cardiac monitoring are established. Nothing should be placed in the patient's mouth, and the patient should be protected from injury.
Phase 2: First-Line — Benzodiazepines (5-20 Minutes)
| Agent | Route | Dose | Max | Key Feature |
|---|---|---|---|---|
| Lorazepam | IV | 0.1 mg/kg | 4 mg/dose (repeat x1) | Preferred IV agent (longer CNS duration) |
| Midazolam | IM | 0.2 mg/kg | 10 mg | No IV needed; RAMPART trial |
| Midazolam | IN | 0.2 mg/kg | 5 mg/nostril | Pediatric/no-IV option |
| Diazepam | IV | 0.15–0.2 mg/kg | 10 mg | Short duration; needs follow-up agent |
| Diazepam | PR | 0.2–0.5 mg/kg | — | Pediatric home rescue |
IV lorazepam at 0.1 mg/kg (maximum 4 mg per dose), repeated once in 5 minutes if needed, is the preferred IV agent because of its longer duration of action in the CNS. IM midazolam at 0.2 mg/kg (maximum 10 mg) is used when no IV access is available — the RAMPART trial demonstrated that IM midazolam was superior to IV lorazepam in the prehospital setting because it could be administered faster. IV diazepam at 0.15 to 0.2 mg/kg (maximum 10 mg) has a short duration of action and requires follow-up with a longer-acting agent. Intranasal midazolam at 0.2 mg/kg (maximum 5 mg per nostril) is useful in pediatrics and when no IV access is available. Rectal diazepam at 0.2 to 0.5 mg/kg is used in pediatric home rescue protocols. The critical message is to use adequate doses — under-dosing is the most common and most dangerous error.
Phase 3: Second-Line Agents (20-40 Minutes)
Second-line agents are used when seizures persist after two adequate doses of benzodiazepines. The ESETT trial demonstrated that levetiracetam, fosphenytoin, and valproate are equally effective as second-line agents for benzodiazepine-refractory status epilepticus, each with approximately 45 percent success rate.
| Agent | Dose | Infusion Time | Advantages | Disadvantages |
|---|---|---|---|---|
| Levetiracetam | 60 mg/kg IV (max 4500 mg) | 15 min | No cardiac monitoring, no interactions, safe in liver disease | Behavioral side effects |
| Fosphenytoin | 20 mg PE/kg IV | Max 150 mg PE/min | Extensive experience, measurable levels | Cardiac monitoring required, hypotension, Purple Glove risk |
| Valproate | 40 mg/kg IV (max 3000 mg) | 10 min | Broad-spectrum, rapid infusion, hemodynamically stable | Hepatotoxicity, teratogenic, contraindicated in mitochondrial disorders |
Levetiracetam (Keppra) is dosed at 60 mg/kg IV (maximum 4500 mg) over 15 minutes. Its advantages include no need for cardiac monitoring, no drug interactions, and safety in hepatic impairment. Behavioral side effects (agitation and irritability) are the main disadvantage.
Fosphenytoin is dosed at 20 mg phenytoin equivalents per kilogram IV (maximum infusion rate 150 mg PE/min). It has the advantage of extensive clinical experience and measurable levels. Disadvantages include the need for cardiac monitoring (risk of hypotension and arrhythmias), contraindication in cardiac conduction abnormalities, ineffectiveness in many genetic epilepsies, and the risk of Purple Glove syndrome with peripheral IV phenytoin (fosphenytoin is safer in this regard).
Valproate (Depakote) is dosed at 40 mg/kg IV (maximum 3000 mg) over 10 minutes. It is a broad-spectrum agent with rapid infusion capability and good hemodynamic tolerance. Disadvantages include hepatotoxicity (it should be avoided in liver disease), pancreatitis risk, teratogenicity, drug interactions, and contraindication in mitochondrial disorders and urea cycle defects.
Phase 4: Refractory SE (> 40 Minutes)
Refractory status epilepticus requires continuous IV anesthetic infusions, which necessitate intubation and ICU admission. Midazolam infusion (0.2 mg/kg bolus, then 0.05 to 2 mg/kg/hr) is the easiest to titrate with the lowest hemodynamic effects. Propofol infusion (1 to 2 mg/kg bolus, then 20 to 80 mcg/kg/min) carries the risk of propofol infusion syndrome (PRIS) with prolonged use, requiring monitoring of triglycerides, CK, and lactate. Pentobarbital (5 to 15 mg/kg bolus, then 0.5 to 5 mg/kg/hr) is the most potent option but causes the greatest hemodynamic compromise and is reserved for truly refractory cases. Ketamine is emerging as a third-line or adjunctive agent — as an NMDA receptor antagonist it may be neuroprotective and does not cause hemodynamic depression — dosed at 1 to 3 mg/kg bolus and 1 to 10 mg/kg/hr infusion. The goal is EEG burst suppression for 24 to 48 hours, followed by gradual wean.
Super-Refractory SE
When status epilepticus persists beyond 24 hours despite anesthetic therapy, additional considerations include immunotherapy (if an autoimmune etiology is suspected), the ketogenic diet, electroconvulsive therapy, and hypothermia. An autoimmune encephalitis workup should be sent, including antibodies against NMDA receptors, LGI1, CASPR2, GABA-B, and AMPA.
Special Populations
Pediatric SE
Weight-based dosing is critical in children, and a Broselow tape or age-based dosing should be used. First-line agents are IV lorazepam 0.1 mg/kg or IM midazolam 0.2 mg/kg. Febrile status epilepticus is the most common cause of SE in children under 5 years and generally carries an excellent prognosis. In neonatal seizures, phenobarbital remains the first-line agent at a 20 mg/kg loading dose.
Eclamptic Seizures
Magnesium sulfate is the agent of choice for eclamptic seizures, not benzodiazepines. A loading dose of 4 to 6 g IV is given over 15 to 20 minutes, followed by a maintenance infusion of 1 to 2 g/hr. If seizures persist despite magnesium, lorazepam 2 to 4 mg IV is administered.
Alcohol Withdrawal Seizures
Benzodiazepines are the first-line treatment for alcohol withdrawal seizures and are usually sufficient. Phenytoin is not effective for alcohol withdrawal seizures. Phenobarbital should be considered for benzodiazepine-resistant alcohol withdrawal status epilepticus.
Workup for New-Onset SE
Emergent Evaluation
The emergent workup includes glucose, electrolytes (sodium, calcium, and magnesium), renal function, anticonvulsant levels (if the patient takes anticonvulsants), a toxicology screen, CT head (once stabilized, to rule out a structural cause), lumbar puncture (if infection is suspected, once safe to perform), and continuous EEG monitoring (especially if the patient is not returning to baseline after seizure cessation, to rule out NCSE).
Consider
Additional workup to consider includes an autoimmune encephalitis panel, infectious workup (CSF studies and blood cultures), MRI of the brain (when feasible), and metabolic studies in children.
<image>A treatment algorithm flowchart for status epilepticus. At 0-5 minutes: stabilization, glucose check, IV access. At 5-20 minutes: first-line benzodiazepines — IV lorazepam 0.1 mg/kg (max 4 mg, repeat once) or IM midazolam 0.2 mg/kg (max 10 mg) if no IV access. At 20-40 minutes: second-line agents if seizures persist — three equal options shown in parallel boxes: levetiracetam 60 mg/kg IV (max 4500 mg), fosphenytoin 20 PE/kg IV, or valproate 40 mg/kg IV (max 3000 mg). With "ESETT trial: all three equally effective (~45%)" noted. At 40+ minutes: refractory SE — intubate, continuous EEG, ICU; options include midazolam infusion, propofol infusion, or pentobarbital infusion, with goal of burst suppression on EEG.</image>
<image>A diagram illustrating the pathophysiology of benzodiazepine resistance in prolonged status epilepticus. The top panel shows a normal neuron with GABA-A receptors on the cell surface, with benzodiazepine binding sites available. The bottom panel shows a neuron after prolonged seizure activity (greater than 30 minutes), with GABA-A receptors internalized into the cytoplasm (endocytosis), reducing the number of surface targets for benzodiazepines. Simultaneously, NMDA receptors are shown being trafficked to the cell surface, creating excitotoxicity. Annotations explain why early, adequate benzodiazepine dosing is critical and why NMDA antagonists like ketamine may have a role in refractory SE.</image>
Clinical Pearls
Under-dosing benzodiazepines is the single most common and most dangerous error in status epilepticus management — full weight-based doses must be used. IM midazolam is as effective as IV lorazepam and faster to administer when no IV access exists, as demonstrated by the RAMPART trial. The ESETT trial showed that levetiracetam, fosphenytoin, and valproate are equally effective second-line agents, and the choice depends on patient factors and availability. Up to 20 percent of patients who stop convulsing are in non-convulsive status epilepticus — if the patient does not return to baseline, an EEG should be obtained. GABA receptor internalization during prolonged seizures creates pharmacoresistance, which is why the first dose must be adequate and timely. Phenytoin is not effective for alcohol withdrawal seizures — benzodiazepines must be used. Magnesium sulfate is the first-line agent for eclamptic seizures, not benzodiazepines. Glucose should always be checked because hypoglycemia causes seizures and is immediately treatable.
References
- Silbergleit R, et al. Intramuscular versus intravenous therapy for prehospital status epilepticus (RAMPART). NEJM. 2012;366:591-600.
- Kapur J, et al. Randomized trial of three anticonvulsant medications for status epilepticus (ESETT). NEJM. 2019;381:2103-2113.
- Brophy GM, et al. Neurocritical Care Society Status Epilepticus Guideline Writing Committee. Neurocrit Care. 2012;17:3-23.
- Glauser T, et al. Evidence-based guideline: treatment of convulsive status epilepticus in children and adults. Epilepsy Curr. 2016;16:48-61.
- Treiman DM, et al. A comparison of four treatments for generalized convulsive status epilepticus. NEJM. 1998;339:792-798.
